Product Reports Resources Pricing Login Book a demo

Singlera Genomics

Biotech & Life Sciences · San Diego, United States · Founded 2013

A developer of 'liquid biopsy'​ analysis reagents and software, focusing on determing methylation haplotypes across many thousands of genomic locations in cell-free DNA MoreLess

Singlera Genomics is a company that specializes in liquid biopsy for non-invasive early cancer detection. The company has developed proprietary technologies for analyzing cell-free DNA (cfDNA) methylation, which allows for the early detection of various types of cancer.

Their product portfolio includes assays for different cancers, such as the PDACatch for pancreatic cancer, which has received Breakthrough Device Designation from the FDA, and ColonAiQ for colorectal cancer, which has been approved by the NMPA in China. The company's business model revolves around the development and commercialization of these diagnostic tests. They serve high-risk individuals and the broader healthcare market, providing tools for cancer screening, diagnosis, and monitoring. Singlera Genomics operates globally with locations in the US and China and generates revenue through the sale of its diagnostic products and services.

Keywords: liquid biopsy, cancer diagnostics, genomics, cfDNA, methylation, oncology, early detection, non-invasive, molecular diagnostics, precision medicine

Valuation $0–100M
Headcount <100
Total funding $100–500M
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Singlera Genomics and the history behind them.

Talent graph

Singlera Genomics's talent

Book a demo to see the people
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

24 investors on Singlera Genomics's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 21 investors entered at this stage
Lilly Asia Ventures
CD Capital
Green Pine Capital
Prosperico Ventures
CICC
FTZ Fund Management
Proxima Ventures
Wuxi Capital
Huamei Group
Detong Capital
Linden Asset Management
Fudan University Ningbo Research Institute
FutureX Capital
Sansure Biotech
Galaxy Yuanhui Investment
Forstone Capital
Shengxiang Bio
Gandao Fund
Qiandao Fund
Fengshi Capital
Bai Shide
Series B+ 3 investors entered at this stage
Junci Investment
Yangzhou Longchuan Holding Group
Guojin Group

Global footprint

Where Singlera Genomics has talent and traffic

Workforce by country
3 countries with
team presence
🇨🇳 China71.4%
🇺🇸 United States21.4%
🇳🇱 Netherlands7.1%
3 countries shown

Market sentiment

What the market is saying about Singlera Genomics

An AI-synthesized read of the highest-engagement posts about Singlera Genomics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Singlera Genomics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles